CURE Pharmaceutical Holding Corp (OTCMKTS:CURR) has launched an initiative for the clinical development of psychedelic compounds such as LSD, MDMA, and psilocybin for treating different mental health disorders.
CURE to optimize psychedelics using the CUREfilm® platform
The company plans to optimize psychedelics actives metabolism and absorption using its patented oral film platform CUREfilm® to target clinical efficacy for microdosing and macrodosing treatment regimens. CJURE Pharmaceuticals will use its DEA Schedule 1 license and cGMP-certified and FDA-registered facility, offering a US footprint for expected commercialization.
CURE CEO Rob Davidson said that its specialty pharmaceutical pipeline is strong and protected by its IP. It is differentiated compared to other entities developing psychedelics. Through selective diversification and innovation, Davidson is confident that the new psychedelics programs and corresponding product development initiatives will open the doors for more research and new solutions for patients. Besides broadening the company’s internal pipeline, the programs also reflect its focus on a novel treatment for critical disease states that include viral infections, central nervous system disorders, and mental health disorders.
Psychedelics showing potential in treating various disorders
Continuing research which has been active for decades, continues to showcase growing psychedelic evidence supporting mental health disorders treatment. Some of the disorders for consideration include PTSD, depression, anxiety, addiction disorders, and obsessive-compulsive disorder. For instance, in 2017, the FDA acknowledged MDMA’s potential benefits by issuing a Breakthrough Therapy Designation to an MDMA therapy in PTSD treatment. Two years ago, The Johns Hopkins University launched the “Centre for Psychedelic and Consciousness Research.”
Jonathan Berlent, Cure’s Chief Business Officer, said that they are dedicated to applying film technology to leading compounds in unmet need, high-impact areas. He said that advancing psychedelic product development programs helps ensure the company’s end goal of targeting patients that would have been left without a treatment alternative. He added that the company will advance its programs in a thoughtful, fiscally-responsible, and strategic way. The psychedelic drug market is expected to grow at 16.3% CAGR through 2027 to reach around $6.8 billion.